Roche up in arms as NICE advises NHS not to use Perjeta
This article was originally published in Scrip
NICE, the health technology assessment institute for England and Wales, is gearing up to advise the NHS that Roche's breast cancer drug Perjeta (pertuzumab) should not be routinely used as it is not value for money. The Swiss pharma company has responded with strong criticism of the Department of Health (DH), which has delayed a review of the company's proposed patient access scheme, accusing it of letting patients down and pointing to flaws in the UK's "creaking system."
You may also be interested in...
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.
Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.
Some of you will be familiar with it, many of you may not even have heard of it, but the pharmaceutical industry needs to know about it; we're talking about Canada's pan-Canadian Pharmaceutical Alliance (pCPA). Currently run with no formal office or resources, by people who have taken it on as extra work on top of their usual day job, the pCPA has still managed to become a formidable market access force in Canada since its inception in 2010. Its decisions are make or break for pharmaceutical companies targeting the market, and changes on the horizon mean its importance is set to increase.